On March 27, 2019, Dr. Song Ruilin, Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA) met with Mr. Tim White, Commercial Consul of Australian Trade and Investment Commission (Austrade) in Shanghai, having a deep discussion on how to promote exchanges and cooperation of pharmaceutical innovation between China and Australia, and bring high quality pharmaceutical innovative projects into Chinese market.

Dr. Song pointed out that China could learn rich experience of clinical trial and pharmaceutical R&D from Australia, meanwhile, resting on the huge number of patients and market size in China, Australia could have access to a vast market of medical products. Now, China has put pharmaceutical as one of the top strategic industries, and we are looking forward to increasing bilateral exchanges and cooperation of pharmaceutical innovation.

Dr. Song introduced the 2019 China BioMed Innovation and Investment Conference (2019 CBIIC) scheduled to be held in Suzhou on September 21-23 this year, and hoped that Australia could select superior pharmaceutical innovation projects to participate in this event.

Mr. Tim White expressed that Austrade would provide active support to 2019 CBIIC, by which could not only assist Australia pharmaceutical companies in expanding Chinese market and spotting business partners, but also present Chinese pharmaceutical and capital industry more high quality pharmaceutical innovation projects from Australia.

After having a deep discussion on upcoming cooperation, both sides expressed the willingness to work together for the development of pharmaceutical innovation in China and Australia.

PhIRDA Executive President Song Ruilin and Austrade Commercial Consul Tim White 

Ms. Lu Xiaoti, Deputy Secretary-General of PhIRDA, Mr. Li Gen, Project Assistant of International Affairs attended the meeting.